An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity

An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity

Abstract Background Resistance to immune checkpoint inhibitor (ICI) therapy narrows the efficacy of cancer immunotherapy. Although 4-1BB is a promising drug target as a costimulatory molecule of immune cells, no 4-1BB agonist has been given clinical approval because of severe liver toxicity or limit...

Full description

Bibliographic Details
Main Authors: Lian-sheng Cheng, Min Zhu, Yan Gao, Wen-ting Liu, Wu Yin, Pengfei Zhou, Zhongliang Zhu, Liwen Niu, Xiaoli Zeng, Dayan Zhang, Qing Fang, Fengrong Wang, Qun Zhao, Yan Zhang, Guodong Shen
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Cellular & Molecular Biology Letters
Subjects:
Colorectal cancer
Cancer immunotherapy
4-1BB/CD137
PD-1/PD-L1
Immune checkpoint inhibitor
Antitumor immunity
Online Access:https://doi.org/10.1186/s11658-023-00461-w

Internet

https://doi.org/10.1186/s11658-023-00461-w

Similar Items